The resulting damage from high glucose levels further increases oxidative stress, creating a cycle that can lead to complications like neuropathy, nephropathy, and retinopathy

Back to Journals Clinical Pharmacology: Advances and Applications Volume 17 Pharmacotherapy for Obesity: Recent Updates Authors Fredrick TW, Camilleri M , Acosta A Received 21 March 2025 Accepted for publication 7 September 2025 Published 19 September 2025 Volume 2025:17 Pages 305327 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Khaled Deeb Thomas Ward Fredrick, Michael Camilleri, Andres Acosta Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905, USA Correspondence: Michael Camilleri, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905, USA, Tel +1-507-266-2305, Email [email protected] Abstract: In this narrative review we describe the recent updates regarding anti-obesity medications as of February 2025

When to Pause or Restart GLP-1 Therapy Life circumstancespregnancy planning, surgery, temporary financial constraintssometimes require pausing GLP-1 treatment
Possible Orlistat side effects include gas, increased bowel movements, and fecal incontinence
Furthermore, BPC-157 appeared to hasten the dispersion of tendon fibroblasts across culture plates
The short answer: You can begin with your primary care clinician, a specialist in obesity medicine, or in some cases a telehealth provider